Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34<sup>+</sup> cell therapy: A clinical trial
In conclusion, our findings suggest that repetitive peripheral blood-derived autologous CD34<sup>+</sup> cell transplantation into the renal arteries is safe, feasible, and may be effective for patients with progressive CKD. However, a large-scale clinical trial is warranted to validate the efficacy of repetitive regenerative cell therapy using autologous CD34<sup>+</sup> cells in patients with progressive CKD.
Authors
- Toshitaka Tsukiyama
- Kunihiro Ishioka (ORCID: https://orcid.org/0000-0001-9129-5075)
- Shuzo Kobayashi (ORCID: https://orcid.org/0000-0003-2373-814X)
- Takayasu Ohtake (ORCID: https://orcid.org/0000-0002-7009-161X)
- Sumi Hidaka (ORCID: https://orcid.org/0000-0002-1576-0868)
- Ayaka Mitomo (ORCID: https://orcid.org/0009-0008-3222-0960)
- Mizuki Yamano
- Takayuki Asahara (ORCID: https://orcid.org/0000-0001-8272-2055)
- Machiko Oka
- Yasuhiro Mochida
- Hidekazu Moriya (ORCID: https://orcid.org/0000-0002-3252-2976)
- Haruka Maruyama
- Tsutomu Sato (ORCID: https://orcid.org/0000-0003-2712-2713)
- Suguru Muraoka
- Haruchika Masuda
Institutions
- Shonan Kamakura General Hospital (JP)
Publication Details
- Journal
- World Journal of Stem Cells
- Published
- 2024-12-12
- DOI
- https://doi.org/10.4252/wjsc.v16.i12.1012
- Citations
- 2
- Primary Topic
- Tissue Engineering and Regenerative Medicine
- Type
- article
- Field-Weighted Citation Impact
- 1.15